



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 10/28/04

Signature: [Signature]

(Ginny Blundell)

Docket No.: AREX-P03-005  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Madiyalakan et al.

Application No.: 10/824,554

Confirmation No.: 6247

Filed: April 14, 2004

Art Unit: 1641

For: METHOD FOR DIAGNOSING EFFICACY  
OF XENOTYPIC ANTIBODY THERAPY

Examiner: Not Yet Assigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

MS Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is not supplied because the references were previously cited by or submitted to the Office in a prior application number 09/871,339, filed May 31, 2001 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to be an

admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Supplemental Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. AREX-P03-005.

Dated: 10/25/04

Respectfully submitted,

By Lisa M. Treannie

Lisa M. Treannie

Registration No.: 41,368

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



Substitute for form 1449A/B/PTO

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	1	of	2	Application Number	10/824554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	AREX-P03-005

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A10	4,940,670	7/10/90	Rhodes	
	A11	4,950,480	8/21/90	Barber et al.	
	A12	4,997,762	3/5/91	Hanna, Jr. et al.	
	A13	5,053,224	10/1/91	Koprowski et al.	
	A14	5,183,657	2/2/93	Buurman	
	A15	5,308,614	5/3/94	Hakomori	
	A16	5,194,254	3/16/93	Barber et al.	
	A17	5,389,530	2/14/95	Hakomori	
	A18	5,478,556	12/26/95	Elliott et al.	
	A19	5,500,215	3/19/96	Hakomori	
	A20	5,009,888	4/23/91	Dunn	
	A21	5,518,723	5/21/96	Devico et al.	
	A22	5,013,547	5/7/91	Sweet et al.	

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	EP 0 153 871	9/4/85	Tse Wen Chang		
	B2	EP 0288082	4/22/88	Europe		
	B3	PCT/EP94/01719	8/12/94	PCT		
	B4	PCT/US90/03142	STAT	PCT		
	B5	PCT/US92/11334	7/8/93	PCT		
	B6	WO 89/01629	2/23/89	PCT		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Abstract of Golumbek et al., Immunologic Research, 1993, pp. 183-192, Vol. 12.	
	C2	Abstract of Hilkens et al., Cancer Letters, 1995, pp. 27-33, Vol. 90.	
	C3	Baum et al., Hybridoma, 1993, pp. 583-589, Vol. 12.	
	C4	Baum et al., Cancer, 1994, pp. 1121-1125, Vol. 73.	
	C5	Chatterjee et al., Cancer Immunol Immunother, 1994, pp. 75-82, Vol. 38.	

Examiner Signature	Date Considered
--------------------	-----------------



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/824554
				Filing Date	April 14, 2004
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	AREX-P03-005

C6	Colman, "Structure of Antibody-Antigen Complexes: Implications for Immune Recognition," Advances in Immunology, 1988, pp. 99-132, Vol. 43.	
C7	Ghiron et al., Photochemistry and Photobiology, 1968, pp. 87-92, Vol. 7.	
C8	Gura, Science, 1997, pp. 1041-1042, Vol. 278.	
C9	Herbert et al., Dictionary of Immunology, Academic Press, London, 1995, pp. 58; 59, 72, 73, and 154.	
C10	Imai et al., Acta Pathol, Japan, 1989, pp. 43-49, Vol. 29.	
C11	Jacobs et al., "Clinical Use of Tumor Markers in Oncology," Current Problems in Cancer, 1991, pp. 299-350.	
C12	Jose et al., Molecular Immunology, 1987, pp. 1145-1150, Vol. 24.	
C13	Kallenbach et al., Curr. Stud Hematol Blood Transfus, 1989, pp. 70-82.	
C14	Kehoe, S., International Journal of Oncology, 1995, pp. 451-458, Vol. 6.	
C15	Kleckowski et al., Photochem. Photobiol., 1962, pp. 299-304, Vol. 1.	
C16	Lanzavecchia, "Mechanisms of antigen uptake for presentation," Current Opinion in Immunology, 1996, pp. 348-354, Vol. 8.	
C17	Lanzavecchia, Science, 1993, pp. 937-944, Vol. 260.	
C18	Leoni et al., Int J Cancer, 1987, pp. 592-597, Vol. 40.	
C19	Madiyalakan et al., "OVAREX™ MAb-B43.13:IFN-γ Could Improve the Ovarian Tumor Cell Sensitivity to CA125-Specific Allogenic Cytotoxic T Cells," Hybridoma, 1997, pp. 41-45, Vol. 16.	
C20	Madiyalakan et al., Hybridoma, 1995, pp. 199-203, Vol. 14.	
C21	Murray et al., J.A.M.A., 1955, pp. 8-14.	
C22	Nemazee et al., PNAS, 1982, pp. 3828-3832, Vol. 79.	
C23	Noujaim et al., Current Tumor Diagnosis, 1994, pp. 823-829.	
C24	Prodouze et al., Blood, 1987, pp. 589-592, Vol. 70.	
C25	Simitsek et al., "Modulation of Antigen Processing by Bound Antibodies Can Boost or Suppress Class II Major Histocompatibility Complex Presentation of Different T Cell Determinants," Journal of Experimental Medicine, 1995, pp. 1957-1963, Vol. 181.	
C26	Stevenson et al., Immunol, 1994, pp. 16-19, Vol. 2.	
C27	Sykes et al., The Journal of Nuclear Medicine, 1995, pp. 1913-1922, Vol. 36.	
C28	Thomson et al., Clin Exp Immunol, 1994, pp. 351-357, Vol. 98.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--